Short traders are more bearish on shares of the company if you put credence in the increase in short interest. The stock had a rise in short interest from September 29, 2017 to October 13, 2017 of 6.35%. Short interest grew 523,485 over that timeframe. With short interest at 8,773,220 and short average daily volume at 2,378,158, days to cover is 4.0 and the percentage of shorted shares was 0.01% on October 13.
Here is a rundown on some insider market activity for Amgen Inc. (NASDAQ:AMGN). Sean E. Harper, EVP, Research & Development disclosed the sale of 1,525 shares of (AMGN). The shares were purchased at an average price of $185.95. Harper now owns $11,000,058 of the stock according to the SEC filing.
The following firms have recently changed their position in AMGN. As of quarter end Finemark National Bank & Trust had bought 2,122 shares growing its holdings by 7.4%. The value in dollars went from $4,954,000 to $5,759,000 a change of $805,000 for the reporting period. As of the end of the quarter Andra Ap-fonden had acquired a total of 1,700 shares growing its stake by 4.5%. The value of the investment in AMGN increased from $6,493,000 to $7,346,000 increasing 13.1% quarter over quarter.
Affinity Investment Advisors, LLC added to its holdings by buying 22,459 shares an increase of 35.0% as of 09/30/2017. Affinity Investment Advisors, LLC owns 86,669 shares valued at $16,159,000. The total value of its holdings increased 46.1%. Artemis Investment Management LLP cut its position by selling 1,628 shares a decrease of 1.2% from 06/30/2017 to 09/30/2017. Artemis Investment Management LLP claims 138,249 shares worth $25,763,000. The value of the position overall is up by 6.9%.
July 26 investment analysts at UBS maintained a stock rating of “Neutral” and moved up the price target to $185.00 from $168.00. On September 15 analysts at RBC Capital started coverage by announcing an initial rating of “Sector Perform”.
On September 29 Credit Suisse kept the stock rating at “Outperform” and lowered the price target from $205.00 to $186.00. October 6 investment analysts at Morgan Stanley maintained a company rating of “Overweight” and raised the price expectation to $196.00 from $189.00.
On October 13 Barclays made no change to the company rating of “Equal-Weight” but raised the price target from $185.00 to $190.00. October 26 investment analysts at Morgan Stanley kept the company rating at “Overweight” but lowered the price expectation from $196.00 to $193.00.
The company is now up by 0.36% since yesterday’s close of $175.22. The company declared a dividend to be paid on Friday the 8th of December 2017. The dividend will be $1.150 per share for the quarter which is $4.60 annualized. This dividend represents a yield of $2.62. The ex-dividend date is Tuesday August 15th, 2017.
The stock last traded at $175.22 which is slightly below the 50 day moving average of $184.39 and slightly over the 200 day moving average of $172.38. The 50 day moving average was down by -4.97% and the 200 day average went up $2.84 or +1.65%.
Amgen Inc.’s P/E ratio is 15.96 and market capitalization is 127.85B. In the last earnings report the EPS was $10.98 and is projected to be $12.66 for the current year with 729,674,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $3.14 with next year’s EPS anticipated to be $12.78.
Amgen Inc., launched on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Business’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience..